Dow Jones Newswires: Ipsen to acquire U.S.-based Epizyme for $247 million.

Read Time:6 Second

The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

Chip designer Qualcomm Inc. could be the sleeper stock of the AI hardware boom.

Shares of used-car retailer Carvana Co. jumped about 40% in the extended session Wednesday after a surprise profit and larger...

High-yield, or “junk bonds,” outperformed in a turbulent April for financial assets

A look at whether rival retailers should be worried or encouraged by Walmart shuttering its health centers.

A weekly look at the most important news and moves in crypto, and what’s on the horizon in digital assets.

Japan’s yen violently strengthened against the U.S. dollar late Wednesday, sparking suspicions of intervention by Japanese authorities.